Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive bone erosion. Leflunomide is originally developed to suppress inflammation via its metabolite A77 1726 to attenuate bone erosion. However, distinctive responsiveness to Leflunomide is observed among RA individuals. The research work done by Research Assistant Professor Chao Liang was published in “Nature Communications” (Journal Impact Factors: 11.880). The work entitled “HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis” presented a precision medicine-based therapeutic strategy for rheumatoid arthritis.